CYAD - セリアド (Celyad SA) セリアド

 CYADのチャート


 CYADの企業情報

symbol CYAD
会社名 Celyad SA (セリアド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   セリアドはベルギ―のバイオ医薬品企業。主に心不全や心筋梗塞などの心臓疾患の治療法の発見、開発、商業化に従事する。バイオ治療薬を心臓の筋肉に注入するためのカテ―テル「C-CATHez」を提供。また、慢性心不全や虚血性心筋症の治療向けに臨床段階の主力薬剤である「C-Cure」を提供する。新薬候補にはタンパク質ベ―スの薬剤も扱う。   
本社所在地 Rue Edouard Belin 12 Mont-Saint-Guibert 1435 BEL
代表者氏名
代表者役職名
電話番号
設立年月日 39264
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 76人
url www.C3BS.com
nasdaq_url https://www.nasdaq.com/symbol/cyad
adr_tso 883561
EBITDA EBITDA ー
終値(lastsale) 25
時価総額(marketcap) 22089025
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 CYADのテクニカル分析


 CYADのニュース

   Celyad Oncology SA: Celyad: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)  2021/06/30 05:04:00 FinanzNachrichten
Regulatory News: Celyad Oncology SA (Euronext Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies f
   Celyad: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)  2021/06/30 05:00:00 Wallstreet:Online
Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced on June 30, 2021, a capital increase of 306,800 new shares of the Company through Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor, and its Open
   H.C. Wainwright Reaffirms Their Buy Rating on Celyad (CYAD)  2021/06/14 10:27:55 Smarter Analyst
In a report released today, Edward White from H.C. The post H.C. Wainwright Reaffirms Their Buy Rating on Celyad (CYAD) appeared first on Smarter Analyst .
   Celyad shares surge ahead of upcoming multiple myeloma study poster presentation  2021/05/13 12:11:01 Seeking Alpha
   Celyad (CYAD) Receives a Buy from H.C. Wainwright  2021/05/13 10:17:23 Smarter Analyst
In a report released today, Edward White from H.C. The post Celyad (CYAD) Receives a Buy from H.C. Wainwright appeared first on Smarter Analyst .
   Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today  2021/01/19 10:50:00 Benzinga
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, …
   Cell And Gene Therapy Market Research, Development, Top Companies, Trends and Growth 2020 to 2030 | Celyad, Cook MyoSite, Cytori Therapeutics, Ferring Pharmaceuticals, Gamida Cell  2020/10/27 04:53:44 OpenPR
The Business Research Company offers "Cell And Gene Therapy Global Market Report 2020-30: COVID-19 Growth And Change" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective
   Trump enfonce la bourse de Toyo | Dividende intérimaire pour Ageas  2020/08/07 05:28:05 L'Echo
La bourse de Hong Kong chute, alors que Trump fait monter la pression contre TikTok et WeChat. Ageas communique le montant de son dividende intérimaire. Celyad et Galapagos à tenir à l'oeil.
   Celyad Oncology publie ses résultats financiers du premier semestre 2020 et les faits marquants du second trimestre  2020/08/06 20:00:00 Business Wire
Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), une société de biotechnologie au stade c
   "Les marchés attendent de voir quelle forme aura le plan de relance US"  2020/08/06 09:46:39 L'Echo
Les marchés européens se replient, dans un climat général de prudence alimentée par les perspectives de la BoE. VGP ajuste le tir sur ses résultats et bondit en bourse. Déferlante de chiffres trimestriels (Adidas, Celyad, Fagron, Galapagos, ING, KBC, Lufhtansa, Montea…).
   Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today  2021/01/19 10:50:00 Benzinga
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, …
   Cell And Gene Therapy Market Research, Development, Top Companies, Trends and Growth 2020 to 2030 | Celyad, Cook MyoSite, Cytori Therapeutics, Ferring Pharmaceuticals, Gamida Cell  2020/10/27 04:53:44 OpenPR
The Business Research Company offers "Cell And Gene Therapy Global Market Report 2020-30: COVID-19 Growth And Change" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective
   Trump enfonce la bourse de Toyo | Dividende intérimaire pour Ageas  2020/08/07 05:28:05 L'Echo
La bourse de Hong Kong chute, alors que Trump fait monter la pression contre TikTok et WeChat. Ageas communique le montant de son dividende intérimaire. Celyad et Galapagos à tenir à l'oeil.
   Celyad Oncology publie ses résultats financiers du premier semestre 2020 et les faits marquants du second trimestre  2020/08/06 20:00:00 Business Wire
Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), une société de biotechnologie au stade c
   "Les marchés attendent de voir quelle forme aura le plan de relance US"  2020/08/06 09:46:39 L'Echo
Les marchés européens se replient, dans un climat général de prudence alimentée par les perspectives de la BoE. VGP ajuste le tir sur ses résultats et bondit en bourse. Déferlante de chiffres trimestriels (Adidas, Celyad, Fagron, Galapagos, ING, KBC, Lufhtansa, Montea…).

 関連キーワード  (― 米国株 セリアド CYAD Celyad SA)

 twitter  (公式ツイッターやCEOツイッターなど)